Biocon Pharma Ltd’s arm has received Health Canada approval for micafungin for injection, aimed at serious fungal infections in both adults and children. The treatment will be used for conditions such as candidemia and esophageal candidiasis, and the approval extends to prophylaxis for stem cell transplant patients. The decision adds a key new offering to Biocon’s portfolio.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
